Safety and Effectiveness of eGERD Device to Reduce Gastroesophageal Reflux Disease (GERD) Symptoms

Inclusion Criteria:

1. Male or female, aged 22 - 75
2. Has been typically suffering from at least three heartburn and/or regurgitation episodes per week during the past three months.
3. Undergone a wireless (Bravo) pH monitoring test during the past 24 months prior to enrollment into the current study, following a 7-day (min.) off-PPI period, with AET ≥6% (as defined in section 7.2) in at least 2 monitoring days AND when averaged over all monitoring days of the test; or, in the absence of such testing, has been determined by the Principal Investigator (PI), based on a detailed anamnesis and with written agreement from the Medical Director, to have gastroesophageal reflux disease (GERD) other than functional GERD; or Undergone a catheter-based pH monitoring test during the past 24 months prior to enrollment into the current study, following a 7-day (min.) off-PPI period, with AET ≥6% (as defined in section 7.2); or, in the absence of such testing, has been determined by the Principal Investigator (PI), based on a detailed anamnesis and with written agreement from the Medical Director, to have gastroesophageal reflux disease (GERD) other than functional GERD.
4. Able and willing to give informed consent for participation in the study and to comply with all study requirements, including operating the smartphone application.
5. Willing to allow his or her General Practitioner and consultant, if appropriate, to be notified of participation in the study.

Exclusion Criteria:

1. Previously undergoing gastric or esophageal surgery
2. Active peptic ulcer disease or symptomatic helicobacter
3. Esophageal or gastric varices or esophageal peptic stricture
4. Severe dysphagia
5. History of suspected or confirmed esophageal or gastric cancer
6. History of any other malignancy in the last 2 years
7. Pregnant women or women intending to become pregnant during the trial period
8. Uncontrolled diabetes mellitus, defined as HbA1c \> 7.5%
9. Severe cardiac conditions such as cardiac arrhythmia or ischemia or cardiac pacemaker / defibrillator
10. Having any implanted electrical device (e.g. sacral nerve stimulation, brain stimulator, others)
11. Known allergy to the device's adhesives/patches
12. Severe pulmonary diseases
13. History of significant multisystem diseases (e.g. kidney failure, liver failure)
14. Known autoimmune or a connective tissue disorder (e.g. scleroderma, CREST-syndrome, Sjogren's Syndrome), requiring therapy in the preceding 2 years
15. History of Barrett's esophagus
16. Para-esophageal hiatal hernia
17. Known history of sliding hiatal hernia ≥4 cm in the last 3 years
18. Known history of erosive esophagitis Grade C or D (LA classification) in the past 5 years
19. Obesity, defined as BMI\>32
20. History of gastroparesis
21. History of fibromyalgia, epilepsy, endometriosis
22. Umbilical hernia \>3cm
23. Past usage experience with the study device
24. Those currently enrolled in any other interventional clinical study
25. Inability to sign the informed consent
26. Inability to understand and fill the reports and questionnaires included in the study
27. Inability to follow the study requisites
28. Other medical conditions/medications that would interfere with subject safety or data collection in the opinion of the PI